Brief: IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results
05/12/2024 13:36
Dec 5 (Reuters) - Icecure Medical Ltd ICCM.O :
* ICECURE'S PROSENSE CRYOABLATION SAFE, EFFECTIVE IN KIDNEY
TUMORS
DESTRUCTION WITH 88.7% RECURRENCE-FREE RATE BASED ON INTERIM
ICESECRET STUDY RESULTS
Source text: ID:nPn8wvVKra
Further company coverage: ICCM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Icecure Medical
See all newsIcecure Medical Ltd reports results for the quarter ended June 30 - Earnings Summary
Israel's IceCure Medical H1 revenue rises on higher system, probe sales
Brief: Icecure Sio Petitions Nccn To Include Cryoablation In Breast Cancer Treatment Guidelines, Citing Icecure's FDA Clearance Of Prosense®
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:45 AM